Nouscom raises $135M in Series D for lead cancer vaccine

lead cancer vaccinePositive

AI Analysis

Summary

Clinical-stage cancer biotech Nouscom raised $135 million in an oversubscribed Series D round to advance its lead cancer vaccine through a Phase 2 study.

Clinical Trial Data

Phase

Phase_2

Outcome Details

Oversubscribed $135M Series D to advance lead vaccine through a Phase 2 study

Importance:7/10

Sentiment:

0.60

Series Dprivate financingcancer vaccineoversubscribedPhase 2oncology

Read the original article

Published by Endpoints News on October 19, 2026 6:00 AM

Read Original